2006
Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB.
Rich M, Socci A, Mitnick C, Nardell E, Becerra M, Bonilla C, Bayona J, Seung K, Furin J, Farmer P, Mukherjee J. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. The International Journal Of Tuberculosis And Lung Disease 2006, 10: 290-6. PMID: 16562709.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsFemaleHumansIncidenceMalePeruResearch DesignRetreatmentRetrospective StudiesRisk FactorsTreatment OutcomeTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryConceptsPrevious treatment exposureRetreatment regimensDrug susceptibility testingPatient populationDST patternsTreatment exposureGroup 1Likely effective drugsMDR-TB regimensSecond-line drugsDrug susceptibility patternsNational Tuberculosis ProgrammeDifferent patient populationsAnti-tuberculosis agentsIndividualized regimensMDR-TBTuberculosis ProgrammeEffective anti-tuberculosis agentsSusceptibility patternsDST resultsRegimensEffective drugsPatientsGroup 4Susceptibility testing
2004
Programmes and principles in treatment of multidrug-resistant tuberculosis
Mukherjee J, Rich M, Socci A, Joseph J, Virú F, Shin S, Furin J, Becerra M, Barry D, Kim J, Bayona J, Farmer P, Fawzi M, Seung K. Programmes and principles in treatment of multidrug-resistant tuberculosis. The Lancet 2004, 363: 474-481. PMID: 14962530, DOI: 10.1016/s0140-6736(04)15496-2.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB treatmentSecond-line anti-tuberculosis drugsSecond-line antituberculosis drugsRetrospective cohort studyAggressive treatment regimensGlobal tuberculosis controlAnti-tuberculosis drugsGreen Light CommitteeResource-poor settingsCohort studyObserved therapyTreatment regimensTreatment adherenceTuberculosis controlResource-poor areasAntituberculosis drugsLower potencyTreatmentTuberculosisDrugsGlobal FundRegimensDosingTherapy
2003
Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from Lima, Peru.
Mukherjee J, Joseph J, Rich M, Shin S, Furin J, Seung K, Sloutsky A, Socci A, Vanderwarker C, Vasquez L, Palacios E, Guerra D, Viru F, Farmer P, Del Castillo H. Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from Lima, Peru. The International Journal Of Tuberculosis And Lung Disease 2003, 7: 637-44. PMID: 12870684.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolDirectly Observed TherapyDrug Resistance, Multiple, BacterialDrug ToleranceHumansPeruTreatment OutcomeTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryConceptsMultidrug-resistant tuberculosisPediatric MDR-TBMonths of therapySecond-line anti-tuberculosis drugsIntermediate outcomesFavorable clinical evolutionShort-course strategyAnti-tuberculosis drugsDOTS-PlusRespiratory insufficiencyRadiographic evidenceClinical evolutionObserved treatmentCase definitionChronic illnessClinical failureCommon causeEarly diagnosisTherapySuch childrenChildrenPatientsTreatmentTuberculosisProgrammatic considerations